High cell density cultivation of a recombinant E. coli strain expressing a key enzyme in bioengineered heparin production

Applied Microbiology and Biotechnology

Volumn 97, Issue 9, 2013, Pages 3893-3900

  Restaino, Odile Francesca ^a,b   Bhaskar, Ujjwal ^b,c   Paul, Priscilla ^b,c   Li, Lingyun ^b,d   De Rosa, Mario ^a   Dordick, Jonathan S ^b,c,e   Linhardt, Robert J ^b,c,d,e  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b RENSSELAER POLYTECHNIC INSTITUTE   (United States)

^c Rensselaer Polytechnic Institute   (United States)

^d Research Rensselaer Polytechnic Institute   (United States)

^e RENSSELAER POLYTECHNIC INSTITUTE   (United States)

Author keywords

Bioengineered heparin; Heparosan; High cell density cultivations; Sulfotransferase

Indexed keywords

CELLS; CLONING; CYTOLOGY; ENZYMES; ESCHERICHIA COLI; INDUSTRIAL MANAGEMENT; MAMMALS; PRODUCTIVITY;

BIOENGINEERED HEPARIN; BIOSYNTHETIC ENZYMES; CHEMO-ENZYMATIC MODIFICATIONS; FERMENTATIVE PRODUCTION; HEPAROSAN; HIGH-CELL-DENSITY CULTIVATIONS; INDUCTION STRATEGIES; SULFOTRANSFERASE;

POLYSACCHARIDES;

6 O SULFOTRANSFERASE 1; BACTERIAL ENZYME; GLYCEROL; GLYCOSAMINOGLYCAN POLYSULFATE; HEPARIN; SULFOTRANSFERASE; UNCLASSIFIED DRUG; ARYL SULFOTRANSFERASE; DISACCHARIDE;

COLIFORM BACTERIUM; CYTOLOGY; ENZYME ACTIVITY; FERMENTATION; RECOMBINATION;

ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BIOENGINEERING; CARBON SOURCE; CELL DENSITY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME SYNTHESIS; ESCHERICHIA COLI; FED BATCH REACTOR; MICROBIAL BIOMASS; NONHUMAN; PROTEIN EXPRESSION; BIOMEDICAL ENGINEERING; BIOSYNTHESIS; ENZYMOLOGY; GENETICS; METABOLISM; METHODOLOGY;

ANIMALIA; ESCHERICHIA COLI; MAMMALIA;

ARYLSULFOTRANSFERASE; BIOMEDICAL ENGINEERING; DISACCHARIDES; ESCHERICHIA COLI; HEPARIN;

EID: 84885900286     PISSN: 01757598     EISSN: 14320614     Source Type: Journal    
DOI: 10.1007/s00253-012-4682-z     Document Type: Article

References (21)

1. Bhaskar U, Sterner E, Hickey AM, Onishi A, Zhang F, Dordick JS, Linhardt RJ (2012) Engineering of routes to heparin and related polysaccharides. Appl Microbiol Biotechnol 93:1-16
2. Carvalho RJ, Cabrera-Crespo J, Tanizaki MM, Gonc¸alves VM (2012) Development of production and purification processes of recombinant fragment of Pneumococcal surface protein A in Escherichia coli using different carbon sources and chromatography sequences. Appl Microbiol Biotechnol 94(3):683-694
3. Chen J, Avci FY, Munoz EM, McDowell LM, Chen M, Pedersen LC, Zhang L, Linhardt RJ, Liu J (2005) Enzymatic redesigning of biologically active heparan sulfate. J Biol Chem 280:42817-42825
4. De Mey M, De Maeseneire S, Soetaert W, Vandamme E (2007) Minimizing acetate formation in E. coli fermentation. J Ind Biotechnol 34:689-700
5. Donovan RS, Robinson CW, Glick BR (1996) Optimizing inducer and culture conditions for expression of foreign proteins under the control of the lac promoter. J Ind Microb 16:145-154
6. Guerrini M, Beccati D, Shriver Z, Naggi AM, Bisio A, Capila I, Lansing J, Guglieri S, Fraser B, Al-Hakim A, Gunay S, Viswanathan K, Zhang Z, Robinson L, Venkataraman G, Buhse L, Nasr M, Woodcock J, Langer R, Linhardt RJ, Casu B, Torri G, Sasisekharan R (2008) Oversulfated chondroitin sulfate is a major contaminant in heparin associated with adverse clinical events. Nat Biotechnol 26:669-775
7. Lee SY (1996) High cell-density culture of Escherichia coli. Tibtech 14:98-105
8. Lindahl U, Li JP, Kusche-Gullberg M, Salmivirta M, Alaranta S, Veromaa T, Emeis J, Roberts I, Taylor C, Oreste P, Zoppetti G, Naggi A, Torri G, Casu B (2005) Generation of "neoheparin"from E. coli K5 capsular polysaccharide. J Med Chem 48:349-352
9. Linhardt RJ (2003) Heparin: Structure and Activity. J Med Chem 46:2551-2554
10. Linhardt RJ, Liu J (2012) Synthetic heparin. Curr Opin Pharmacol 12:217-219
11. Liu H, Zhang Z, Linhardt RJ (2009) Lessons learned from the contamination of heparin. Nat Prod Rep 26:313-321
12. Paul P, Suwan J, Liu J, Dordick JS, Linhardt RJ (2012) Recent advances in sulfotransferase enzyme activity assays. Anal Bioanal Chem 403:1491-1500
13. Restaino OF, Cimini D, De Rosa M, Catapano A, De Rosa M, Schiraldi C (2011) High cell density cultivation of Escherichia coli K4 in a microfiltration bioreactor: a step towards improvement of chondroitin precursor production. Microb Cell Factories 10:10
14. Shiloach J, Fass R (2005) Growing E. coli to high cell density - a historical perspective on method development. Biotechnol Adv 23(5):345-357
15. Wang Z, Ly M, Zhang F, Zhong W, Suen A, Dordick JS, Linhardt RJ (2010) E. coli K5 fermentation and the preparation of heparosan, a bioengineered heparin precursor. Biotechnol Bioengineer 107:964-973
16. Wang Z, Dordick JS, Linhardt RJ (2011a) E. coli K5 heparosan fermentation and improvement by genetic engineering. Bioengineered Bugs 2:1-15
17. Wang Z, Li J, Cheong S, Bhaskar U, Akihiro O, Zhang F, Dordick JS, Linhardt RJ (2011b) Response surface optimization of the heparosan N-deacetylation in producing bioengineered heparin. J Biotechnol 156:188-196
18. Wang Z, Yang B, Zhang Z, Ly M, Takieddin M, Mousa S, Liu J, Dordick JS, Linhardt RJ (2011c) Control of the heparosan Ndeacetylation leads to an improved bioengineered heparin. Appl Microbiol Biotechnol 91:91-99
19. Weng YP, Hsu FC, Yang WS, Chen HP (2006) Optimization of the overexpression of glutamate mutase S component under the control of T7 system by using lactose and IPTG as the inducers. Enzym Microb Technol 38:465-469
20. Zhang Z, McCallum SA, Xie J, Nieto L, Corzana F, Jiménez-Barbero J, Chen M, Liu J, Linhardt RJ (2008) Solution structures of chemoenzymatically synthesized heparin and its precursors. J Am Chem Soc 130:12998-13007
21. Zhang F, Yang B, Ly M, Solakyildirim K, Xiao Z, Wang Z, Beaudet JM, Torelli AY, Dordick JS, Linhardt RJ (2011) Structural characterization of heparins from different commercial sources. Anal Bioanal Chem 401:2793-2803